US healthcare almost broke, Medicare and Social Security's trust funds will have no money by this date
ETHealthWorld The Medicare hospital insurance trust fund is expected to deplete in 2033, three years earlier than last year's projection. Social Security's combined trust funds will run out by 2034, a year earlier than previously forecast.
The financial health of America's two most critical safety-net programs, Medicare and Social Security, is deteriorating faster than expected. An annual report released Wednesday, June 18, by program trustees shows that rising health care costs, demographic pressures, and a new law expanding Social Security benefits have accelerated the timeline for when the programs become out of money and cannot pay full benefits.
The Medicare hospital insurance trust fund is now expected to run out of money in 2033, three years earlier than projected just last year. Meanwhile, Social Security's combined trust funds, which support retirement and disability benefits, will be depleted by 2034, a year earlier than previously forecast.
At that point, beneficiaries would see a significant reduction in monthly payments unless Congress intervenes.The updated projections concern the long-term solvency of these programs, which tens of millions of Americans depend on for health care and income security.
The report highlights that Medicare's hospital insurance (Part A) trust fund faces a steeper decline due to higher-than-expected health care expenses in 2024. The fund posted a surplus of $29 billion last year, but deficits are expected to begin after 2027, leading to full depletion by 2033.Once exhausted, Medicare will only be able to cover 89% of inpatient care costs, such as hospital visits, hospice services, and post-hospital nursing care. Currently, about 68 million people are enrolled in Medicare, including Americans over age 65 and those with severe illnesses or disabilities.Social Security's combined trust funds, which support retirees and disability recipients, are projected to be depleted by 2034, one year earlier than last year's forecast of 2035. After that date, the program would only be able to pay 81% of scheduled benefits, if no changes are made.
This accelerated timeline results in part from the Social Security Fairness Act passed in January 2025. This law repealed the Windfall Elimination Provision and Government Pension Offset, increasing benefits for some workers. Trustees confirmed that this legislative change worsened the trust fund's depletion. Trustees of both programs urged lawmakers to act swiftly. 'Medicare still faces a substantial financial shortfall that needs to be addressed with further legislation,' the report said. Frank Bisignano, the newly appointed Social Security Commissioner, said that stabilizing the trust funds is a top priority for the Trump administration, which has so far pledged not to cut benefits.
Despite this, experts warn that without new revenue or cost controls, both programs risk serious disruption. Nancy Altman of Social Security Works argued that lawmakers must decide: raise revenue or cut benefits. 'There are two options for action,' she said. 'Any politician who doesn't support increasing Social Security's revenue is, by default, supporting benefit cuts.' AARP CEO Myechia Minter-Jordan added that with over 69 million Americans relying on Social Security, 'the stability of this vital program only becomes more important.'The Congressional Budget Office has repeatedly warned that an aging population is the main driver of rising debt related to Social Security and Medicare. The last major Social Security reform occurred about 40 years ago, when the eligibility age was raised from 65 to 67. Medicare eligibility remains at age 65.Several legislative proposals are currently being considered to address the trust funds' financial outlook. However, none have yet been passed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Time of India
8 hours ago
- Time of India
Tripura CM mulls sex education in Class VIII-XII curriculum
Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.
Mint
14 hours ago
- Mint
How weight-loss drugs blew out the US trade deficit
Planes have been jetting from Ireland to the U.S. this year carrying something more valuable than gold: $36 billion worth of hormones for popular obesity and diabetes drugs. The frantic airlift of those ingredients—more than double what was imported from Ireland for all of last year—reflects the collision of two powerful forces: tariff-driven stockpiling and weight-loss drug demand. The peptide and protein-based hormones feed into a category of drugs that include wildly popular GLP-1 treatments and newer types of insulin known as analogues. Taken together the shipments weighed just 23,400 pounds, according to U.S. trade data, equivalent to the weight of less than four Tesla Cybertrucks. Fit into temperature-controlled air cargo containers, the pharmaceutical ingredients have had a huge impact on the U.S. trade imbalance. The shipments have vaulted Ireland, a country of only 5.4 million people, into the second-largest goods-trade imbalance with the U.S., trailing only China. They accounted for roughly half of the $71 billion in goods the U.S. imported from the country in the first four months of the year. Nearly 100% of the imports had a final destination of Indiana, according to U.S. customs records. Eli Lilly, the drug giant behind weight loss and diabetes drugs Zepbound and Mounjaro, is headquartered in Indianapolis. A Lilly spokeswoman declined to comment. President Trump's off-and-on trade war has rewritten global trading patterns this year and—temporarily, at least—widened some of the imbalances he is seeking to eliminate. Companies have scrambled to get shipments to the U.S. ahead of tariff deadlines, with a first round of front-loading ahead of the April 2 announcement, and smaller pushes after the White House paused some of its tariffs. Ireland is at the epicenter of the global rush. It is a major hub for U.S. drug giants, who have been expanding operations there in part because of Ireland's favorable tax policies. Some of the bestselling drugs in the world, such as AbbVie's anti-wrinkle treatment Botox, and U.S. drugmaker Merck's cancer treatment Keytruda, are made in the country. 'It's common sense. It's uncertain at the moment, so you're building a bit of security by stockpiling," said Matt Moran, a consultant and former director of industry group BioPharmaChem Ireland. 'There's such huge demand for those products at the moment." The trade imbalance has put Ireland into an uncomfortable position, landing it earlier this month on the U.S. Treasury Department's monitoring list for currency manipulation, which the government uses to send a warning shot to countries it thinks use unfair trade practices. Ireland's central bank said in a report Thursday that new factories making weight-loss drug ingredients helped drive the country's exports. Ireland's first-quarter economic growth expanded by nearly 10% in the first quarter thanks to the export surge. The attention is 'definitely not welcome," said Dan O'Brien, chief economist of the Institute of International and European Affairs, a Dublin think tank. 'A very big part of the U.S.-EU deficit is accounted for by Ireland alone. Trump doesn't like deficits." The White House wants American drug companies to bring production home and in April ordered a so-called Section 232 investigation that could result in tariffs on both imported drugs and ingredients like hormones. Trump said this week that such tariffs could come 'very soon." Lilly is a force in the market for weight-loss drugs, with sales of its GLP-1 medicines Mounjaro and Zepbound expected to nearly double this year to about $30 billion, according to Bank of America analysts. Maintaining supply of weight-loss drugs has been a challenge for both Lilly and rival Novo Nordisk, the Danish maker of Ozempic and Wegovy. The companies were initially unable to keep up with demand for the drugs. Lilly resolved the shortages faster, helping it to take market share from Novo. Lilly is now preparing for the potential launch of a weight-loss pill, orforglipron, which it plans to submit for U.S. approval later this year. Lilly said it began producing weight-loss and diabetes medicines at its Irish factory in Kinsale in 2023. Novo doesn't produce weight-loss drugs in Ireland, according to a spokeswoman. Peptide and protein-based hormones help to regulate processes such as appetite and metabolism. The category includes hormones that mimic a naturally occurring gut hormone called glucagon-like peptide-1, or GLP-1, but can also be used in some fertility and osteoporosis treatments. Shipping and logistics companies say they have noticed increased demand for pharma shipments, which often travel by air instead of on cheaper ocean freighters because they are so light and valuable. Pharma shipments more than doubled from Ireland to the U.S. in March and April, according to data firm WorldACD. Kuehne + Nagel, a Swiss logistics company with operations in the country, said its teams did overtime to accommodate the increase in booking requests and the customs paperwork. 'We didn't see the same increase from Ireland to the rest of the world. That was not a global trend," said Nico Sacco, the company's senior vice president of healthcare strategy. Imports of vaccines and various other drugs including cancer treatments also increased this year from Ireland, according to trade data. Merck produces cancer treatment Keytruda, the world's bestselling drug, in Ireland, among other places. Merck Chief Executive Rob Davis in April said the company has enough supply to mitigate any impact this year from tariffs and is working on navigating the long-term fallout of tariffs. Merck recently began construction on its first U.S. plant to make Keytruda. Lilly said earlier this year it plans to invest $27 billion in expanding U.S. production. The hormones are often freeze dried and shipped as powders. Obesity-related drugs can fly in the cargo sections of passenger planes, or on cargo flights reserved for pharma products, said Anand Kulkarni, head of global markets at Lufthansa Cargo. Lufthansa saw demand for U.S.-bound pharma shipments from locations such as India, Switzerland and Belgium. Volumes began to dip in April as warehouses in the U.S. reached capacity, he said. To increase shipments, drug companies likely tapped existing stocks and diverted production destined for the rest of the world to the U.S. market instead, industry executives said. 'You can't just switch on capacity. You don't go out and buy machines and start them up," said Moran, the consultant. 'They have to be built, commissioned, validated, and approved by the regulator." Write to Chelsey Dulaney at and Jared S. Hopkins at
